Scientists are on the verge of creating a new scheme of treatment for Parkinson's disease, as recent studies have shown that blocking a particular protein in the brain stops or slows the progression of the disease. It is interesting that as a drug will perform a drug approved for the treatment of leukemia. The results of this promising authors of the study from Johns Hopkins University (USA) have been published in the Journal of Clinical Investigation (The Journal of Clinical Investigation)
Parkinson's disease - a chronic, relentlessly progressive neurological disease characterized by specific movement disorders. Symptoms of this disease include tremors of hands, arms, legs, jaw, twitching of facial muscles, and impaired balance and coordination, rigidity (or stiffness) muscles of the limbs and trunk and bradykinesia (slowness of movement or). As the progression of disease severity of these symptoms is only increasing.
The exact cause of Parkinson's disease has not yet been discovered, but scientists believe that the protein c-Abl is of some importance in the development of pathology, since in many studies suggest an increased activity of this enzyme in patients with Parkinson's disease. In addition, in earlier studies on mice, c-Abl blockade suspends or terminates the progression of Parkinson's disease.
However, Dr. Han Seok Ko, co-author of the study, assistant professor of neurology at Johns Hopkins University, said that the language used in these studies, drugs that blocked c-Abl, inhibits the activity of other, similar to the protein substances, which is why it is not clear whether the therapeutic effect of these funds is caused by an isolated inhibition of c-Abl, or not.
Based on materials http://www.medicalnewstoday.com/articles/311249.php